JP5683108B2 - 癌バイオマーカー - Google Patents
癌バイオマーカー Download PDFInfo
- Publication number
- JP5683108B2 JP5683108B2 JP2009542216A JP2009542216A JP5683108B2 JP 5683108 B2 JP5683108 B2 JP 5683108B2 JP 2009542216 A JP2009542216 A JP 2009542216A JP 2009542216 A JP2009542216 A JP 2009542216A JP 5683108 B2 JP5683108 B2 JP 5683108B2
- Authority
- JP
- Japan
- Prior art keywords
- peptide
- fragment
- prostate cancer
- homeodomain
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000000107 tumor biomarker Substances 0.000 title description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 136
- 206010060862 Prostate cancer Diseases 0.000 claims description 87
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 83
- 238000000034 method Methods 0.000 claims description 78
- 239000012634 fragment Substances 0.000 claims description 77
- 239000000090 biomarker Substances 0.000 claims description 45
- 206010028980 Neoplasm Diseases 0.000 claims description 42
- 210000004027 cell Anatomy 0.000 claims description 41
- 201000011510 cancer Diseases 0.000 claims description 36
- 238000001514 detection method Methods 0.000 claims description 35
- 210000001124 body fluid Anatomy 0.000 claims description 33
- 239000010839 body fluid Substances 0.000 claims description 32
- 239000000523 sample Substances 0.000 claims description 27
- 108010048671 Homeodomain Proteins Proteins 0.000 claims description 24
- 102000009331 Homeodomain Proteins Human genes 0.000 claims description 24
- 108091023040 Transcription factor Proteins 0.000 claims description 23
- 102000040945 Transcription factor Human genes 0.000 claims description 23
- 239000003446 ligand Substances 0.000 claims description 18
- 210000002700 urine Anatomy 0.000 claims description 18
- 210000002966 serum Anatomy 0.000 claims description 17
- 238000012360 testing method Methods 0.000 claims description 17
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 238000011002 quantification Methods 0.000 claims description 14
- 238000012544 monitoring process Methods 0.000 claims description 9
- 239000012472 biological sample Substances 0.000 claims description 8
- 238000002965 ELISA Methods 0.000 claims description 7
- 230000027455 binding Effects 0.000 claims description 7
- 238000001262 western blot Methods 0.000 claims description 7
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 238000003018 immunoassay Methods 0.000 claims description 6
- 238000003753 real-time PCR Methods 0.000 claims description 6
- 230000001225 therapeutic effect Effects 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 5
- 239000008280 blood Substances 0.000 claims description 5
- 239000002245 particle Substances 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 210000001175 cerebrospinal fluid Anatomy 0.000 claims description 4
- 238000004811 liquid chromatography Methods 0.000 claims description 4
- 238000003127 radioimmunoassay Methods 0.000 claims description 4
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 claims description 3
- 238000000672 surface-enhanced laser desorption--ionisation Methods 0.000 claims description 3
- 108091023037 Aptamer Proteins 0.000 claims description 2
- 102100031680 Beta-catenin-interacting protein 1 Human genes 0.000 claims description 2
- 101000993469 Homo sapiens Beta-catenin-interacting protein 1 Proteins 0.000 claims description 2
- 238000005481 NMR spectroscopy Methods 0.000 claims description 2
- 108091034117 Oligonucleotide Proteins 0.000 claims description 2
- 238000003556 assay Methods 0.000 claims description 2
- 238000007877 drug screening Methods 0.000 claims description 2
- 238000011156 evaluation Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 claims description 2
- 229910052737 gold Inorganic materials 0.000 claims description 2
- 239000010931 gold Substances 0.000 claims description 2
- 238000001114 immunoprecipitation Methods 0.000 claims description 2
- 230000006872 improvement Effects 0.000 claims description 2
- 230000003993 interaction Effects 0.000 claims description 2
- 239000004816 latex Substances 0.000 claims description 2
- 229920000126 latex Polymers 0.000 claims description 2
- 238000004949 mass spectrometry Methods 0.000 claims description 2
- 238000002966 oligonucleotide array Methods 0.000 claims description 2
- 210000003296 saliva Anatomy 0.000 claims description 2
- 238000012216 screening Methods 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 229910052709 silver Inorganic materials 0.000 claims description 2
- 239000004332 silver Substances 0.000 claims description 2
- 230000006641 stabilisation Effects 0.000 claims description 2
- 238000011105 stabilization Methods 0.000 claims description 2
- 238000012353 t test Methods 0.000 claims description 2
- 238000004809 thin layer chromatography Methods 0.000 claims description 2
- 101100285412 Gallus gallus EN2 gene Proteins 0.000 claims 15
- 238000009509 drug development Methods 0.000 claims 1
- 239000006249 magnetic particle Substances 0.000 claims 1
- 238000004611 spectroscopical analysis Methods 0.000 claims 1
- 108700005856 engrailed 2 Proteins 0.000 description 93
- 101001002994 Homo sapiens Homeobox protein Hox-C4 Proteins 0.000 description 51
- 102100020759 Homeobox protein Hox-C4 Human genes 0.000 description 49
- 102100025056 Homeobox protein Hox-B6 Human genes 0.000 description 31
- 101001077542 Homo sapiens Homeobox protein Hox-B6 Proteins 0.000 description 30
- 102100029240 Homeobox protein Hox-B5 Human genes 0.000 description 26
- 101000840553 Homo sapiens Homeobox protein Hox-B5 Proteins 0.000 description 26
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 21
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 21
- 108090000623 proteins and genes Proteins 0.000 description 21
- 102100039541 Homeobox protein Hox-A3 Human genes 0.000 description 18
- 101000962622 Homo sapiens Homeobox protein Hox-A3 Proteins 0.000 description 18
- 102000004196 processed proteins & peptides Human genes 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 101001019766 Homo sapiens Homeobox protein Hox-D9 Proteins 0.000 description 17
- 210000001519 tissue Anatomy 0.000 description 17
- 102100034864 Homeobox protein Hox-D9 Human genes 0.000 description 16
- 210000002307 prostate Anatomy 0.000 description 14
- 238000001574 biopsy Methods 0.000 description 11
- 230000014509 gene expression Effects 0.000 description 9
- 238000010186 staining Methods 0.000 description 9
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 7
- 241000283973 Oryctolagus cuniculus Species 0.000 description 7
- 238000011161 development Methods 0.000 description 6
- 230000018109 developmental process Effects 0.000 description 6
- 238000003745 diagnosis Methods 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 5
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 210000004907 gland Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 230000009870 specific binding Effects 0.000 description 5
- 206010020880 Hypertrophy Diseases 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000003211 malignant effect Effects 0.000 description 4
- 230000003287 optical effect Effects 0.000 description 4
- 208000023958 prostate neoplasm Diseases 0.000 description 4
- 241000699666 Mus <mouse, genus> Species 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000001165 lymph node Anatomy 0.000 description 3
- 230000001394 metastastic effect Effects 0.000 description 3
- 206010061289 metastatic neoplasm Diseases 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000000056 organ Anatomy 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 238000004393 prognosis Methods 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 102000007469 Actins Human genes 0.000 description 2
- 108010085238 Actins Proteins 0.000 description 2
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 101150033506 HOX gene Proteins 0.000 description 2
- 208000004403 Prostatic Hyperplasia Diseases 0.000 description 2
- 238000012300 Sequence Analysis Methods 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 238000010804 cDNA synthesis Methods 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000013068 control sample Substances 0.000 description 2
- 210000000805 cytoplasm Anatomy 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 230000001969 hypertrophic effect Effects 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003819 low-pressure liquid chromatography Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 238000011275 oncology therapy Methods 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 210000003934 vacuole Anatomy 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 241000754798 Calophyllum brasiliense Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 1
- 101150040523 EN gene Proteins 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102100030309 Homeobox protein Hox-A1 Human genes 0.000 description 1
- 102100025116 Homeobox protein Hox-A4 Human genes 0.000 description 1
- 102100022650 Homeobox protein Hox-A7 Human genes 0.000 description 1
- 102100028411 Homeobox protein Hox-B3 Human genes 0.000 description 1
- 102100028404 Homeobox protein Hox-B4 Human genes 0.000 description 1
- 102100029433 Homeobox protein Hox-B9 Human genes 0.000 description 1
- 101001083156 Homo sapiens Homeobox protein Hox-A1 Proteins 0.000 description 1
- 101001077578 Homo sapiens Homeobox protein Hox-A4 Proteins 0.000 description 1
- 101001045116 Homo sapiens Homeobox protein Hox-A7 Proteins 0.000 description 1
- 101000839775 Homo sapiens Homeobox protein Hox-B3 Proteins 0.000 description 1
- 101000839788 Homo sapiens Homeobox protein Hox-B4 Proteins 0.000 description 1
- 101000989000 Homo sapiens Homeobox protein Hox-B9 Proteins 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- 102000001399 Kallikrein Human genes 0.000 description 1
- 108060005987 Kallikrein Proteins 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027452 Metastases to bone Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010054107 Nodule Diseases 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 208000025844 Prostatic disease Diseases 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- 108091030071 RNAI Proteins 0.000 description 1
- 238000011530 RNeasy Mini Kit Methods 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 238000000692 Student's t-test Methods 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 238000011394 anticancer treatment Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 210000003050 axon Anatomy 0.000 description 1
- 230000005773 cancer-related death Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001638 cerebellum Anatomy 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 230000009368 gene silencing by RNA Effects 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 238000013537 high throughput screening Methods 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000048380 human HOXC4 Human genes 0.000 description 1
- 210000004408 hybridoma Anatomy 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000006517 limb development Effects 0.000 description 1
- 210000004880 lymph fluid Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 210000004216 mammary stem cell Anatomy 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 1
- 238000002493 microarray Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 230000009826 neoplastic cell growth Effects 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000000683 nonmetastatic effect Effects 0.000 description 1
- 231100001221 nontumorigenic Toxicity 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920006254 polymer film Polymers 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 201000005825 prostate adenocarcinoma Diseases 0.000 description 1
- 210000005267 prostate cell Anatomy 0.000 description 1
- 208000021046 prostate intraepithelial neoplasia Diseases 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000001625 seminal vesicle Anatomy 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 208000000649 small cell carcinoma Diseases 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000002103 transcriptional effect Effects 0.000 description 1
- 206010044412 transitional cell carcinoma Diseases 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 201000010653 vesiculitis Diseases 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57434—Specifically defined cancers of prostate
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6872—Intracellular protein regulatory factors and their receptors, e.g. including ion channels
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- General Physics & Mathematics (AREA)
- Oncology (AREA)
- Hospice & Palliative Care (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Peptides Or Proteins (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0625321.5A GB0625321D0 (en) | 2006-12-19 | 2006-12-19 | Cancer biomarker |
| GB0625321.5 | 2006-12-19 | ||
| GB0719792.4 | 2007-10-10 | ||
| GBGB0719792.4A GB0719792D0 (en) | 2006-12-19 | 2007-10-10 | Cancer biomarkers |
| PCT/GB2007/004902 WO2008075056A1 (en) | 2006-12-19 | 2007-12-19 | Cancer biomarkers |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2010513901A JP2010513901A (ja) | 2010-04-30 |
| JP2010513901A5 JP2010513901A5 (enExample) | 2011-01-27 |
| JP5683108B2 true JP5683108B2 (ja) | 2015-03-11 |
Family
ID=39265269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009542216A Expired - Fee Related JP5683108B2 (ja) | 2006-12-19 | 2007-12-19 | 癌バイオマーカー |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US8460882B2 (enExample) |
| EP (1) | EP2115472B1 (enExample) |
| JP (1) | JP5683108B2 (enExample) |
| CN (1) | CN101675341B (enExample) |
| AU (1) | AU2007335999B2 (enExample) |
| BR (1) | BRPI0720371B8 (enExample) |
| CA (1) | CA2671939C (enExample) |
| CY (1) | CY1115178T1 (enExample) |
| DK (1) | DK2115472T3 (enExample) |
| ES (1) | ES2445185T3 (enExample) |
| GB (2) | GB0625321D0 (enExample) |
| IL (1) | IL199241A (enExample) |
| MX (1) | MX2009006378A (enExample) |
| NZ (1) | NZ577548A (enExample) |
| PL (1) | PL2115472T3 (enExample) |
| PT (1) | PT2115472E (enExample) |
| RU (1) | RU2460075C2 (enExample) |
| SI (1) | SI2115472T1 (enExample) |
| WO (1) | WO2008075056A1 (enExample) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8461126B2 (en) | 2005-10-14 | 2013-06-11 | Phigenix, Inc. | Targeting EN2, PAX2, and/or DEFB1 for treatment of prostate conditions |
| DE102006047617B4 (de) | 2006-10-09 | 2008-11-27 | Clariant International Limited | Verfahren zur Herstellung basischer (Meth)acrylamide |
| DE102008017216B4 (de) | 2008-04-04 | 2013-08-14 | Clariant International Ltd. | Kontinuierliches Verfahren zur Herstellung von Fettsäureamiden |
| GB0823445D0 (en) * | 2008-12-23 | 2009-01-28 | Univ Surrey | Biomarker |
| DE102009031059A1 (de) | 2009-06-30 | 2011-01-05 | Clariant International Ltd. | Vorrichtung zur kontinuierlichen Durchführung chemischer Reaktionen bei hohen Temperaturen |
| WO2011007130A1 (en) * | 2009-07-13 | 2011-01-20 | The University Of Surrey | Therapeutic peptides, polypeptides ans nucleic acid sequences |
| GB0912190D0 (en) * | 2009-07-13 | 2009-08-26 | Univ Surrey | Biomarker |
| GB0912175D0 (en) * | 2009-07-13 | 2009-08-26 | Univ Surrey | Biomarker |
| DE102009042523B4 (de) | 2009-09-22 | 2012-02-16 | Clariant International Ltd. | Vorrichtung und Verfahren zur kontinuierlichen Durchführung heterogen katalysierter chemischer Reaktionen bei hohen Temperaturen |
| DE102009042522A1 (de) | 2009-09-22 | 2011-04-07 | Clariant International Ltd. | Kontinuierliches Umesterungsverfahren |
| GB0921329D0 (en) * | 2009-12-04 | 2010-01-20 | Univ Surrey | Biomarker |
| DE102010056565A1 (de) | 2010-12-30 | 2012-07-05 | Clariant International Ltd. | Verfahren zur Modifizierung Hydroxylgruppen tragender Polymere |
| US20140106363A1 (en) * | 2011-05-12 | 2014-04-17 | Noviogendix Research B.V. | Molecular markers in prostate cancer |
| CA2835728A1 (en) * | 2011-05-12 | 2012-11-15 | Noviogendix Research B.V. | Molecular markers in prostate cancer |
| CN103797120B (zh) * | 2011-09-16 | 2017-04-12 | 上海长海医院 | 前列腺癌的生物学标志物、治疗靶点及其用途 |
| US20140336130A1 (en) * | 2011-12-05 | 2014-11-13 | Phigenix, Inc. | Targeting en2, pax2, and/or defb1 for treatment of prostate conditions |
| WO2014005138A1 (en) * | 2012-06-29 | 2014-01-03 | Kerschensteiner Daniel A | Colorimetric gelatinase assay |
| WO2014025961A1 (en) * | 2012-08-10 | 2014-02-13 | Analiza, Inc. | Methods and devices for analyzing species to determine diseases |
| AU2013388864B2 (en) * | 2013-05-09 | 2017-06-08 | The Procter & Gamble Company | Method and system for assessing health condition |
| WO2016102560A1 (en) * | 2014-12-23 | 2016-06-30 | The University Of Surrey | Glycosylated biomarker |
| KR101698654B1 (ko) | 2014-12-24 | 2017-01-20 | 포항공과대학교 산학협력단 | En2에 특이적으로 결합하는 dna 압타머 및 이의 용도 |
| JP6745820B2 (ja) * | 2015-05-29 | 2020-08-26 | コーニンクレッカ フィリップス エヌ ヴェＫｏｎｉｎｋｌｉｊｋｅ Ｐｈｉｌｉｐｓ Ｎ．Ｖ． | 前立腺がん予後判定の方法 |
| PL3960195T3 (pl) * | 2015-09-23 | 2025-06-09 | Centre National De La Recherche Scientifique | Engrailed do zastosowania w leczeniu stwardnienia zanikowego bocznego |
| CN106282347A (zh) * | 2016-08-17 | 2017-01-04 | 中南大学 | HoxC11作为生物标志物在制备肺腺癌的预诊断试剂中的应用 |
| US10508287B2 (en) | 2016-12-28 | 2019-12-17 | Guangzhou Institutes of Biomedicine and Health Chinese Academy of Sciences | Method for regenerating T cells and applications thereof |
| KR101777085B1 (ko) | 2017-02-23 | 2017-09-11 | 주식회사 성균바이오텍 | En2 단백질의 면역원성 단편 펩타이드 또는 이를 특이적으로 인식하는 항체 조성물 |
| KR101777259B1 (ko) * | 2017-07-14 | 2017-09-13 | 주식회사 무진메디 | En2 단백질을 특이적으로 인식하는 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 |
| KR101777254B1 (ko) * | 2017-07-14 | 2017-09-13 | 주식회사 무진메디 | En2 단백질을 특이적으로 인식하는 특정 항원으로부터 얻어진 단클론 항체 또는 이를 함유하는 전립선암 진단용 조성물 |
| CN107727729A (zh) * | 2017-11-22 | 2018-02-23 | 南宁科城汇信息科技有限公司 | 一种oa候选标志物诊断模型的建立方法 |
| CN107894507A (zh) * | 2017-11-22 | 2018-04-10 | 南宁科城汇信息科技有限公司 | 一种发现和鉴定肝癌血清差异表达蛋白和验证标志物蛋白方法 |
| KR101923199B1 (ko) | 2018-04-25 | 2018-11-28 | 주식회사 무진메디 | 펩스타틴 a를 함유하는 소변 내 en2 진단용 조성물 |
| CN111363817B (zh) * | 2018-12-26 | 2024-02-02 | 广州康立明生物科技股份有限公司 | 基于hoxd12基因的肺癌诊断剂及试剂盒 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0996725A1 (en) * | 1997-06-27 | 2000-05-03 | Human Genome Sciences, Inc. | Human nk-3 related prostate specific gene-1 |
| RU2234942C2 (ru) * | 1998-07-14 | 2004-08-27 | Корикса Корпорейшн | Выделенный опухолевый полипептид предстательной железы и кодирующий его полинуклеотид |
| JP2002527758A (ja) * | 1998-10-19 | 2002-08-27 | ダイアデクスアス・インコーポレーテッド | 前立腺癌を診断、監視、病期分類、イメージング及び治療する方法 |
| AU2001263771A1 (en) | 2000-05-30 | 2001-12-11 | Danmarks Miljo Undersogelser | An assay method and kit for testing biological material for exposure to stress using biomarkers |
| WO2002002806A2 (en) * | 2000-06-30 | 2002-01-10 | Epigenomics Ag | Method and nucleic acids for analysing the methylation of genes implicated in pharmacogenomics |
| US20050079492A1 (en) * | 2000-09-12 | 2005-04-14 | Burgess Jr. Robert M. | Micro-arrayed organization of transcription factor target genes |
| US20040063216A1 (en) | 2000-12-24 | 2004-04-01 | Iser Lubocki | Method for detecting biomarkers |
| NZ527180A (en) | 2000-12-24 | 2007-02-23 | Iser Lubocki | A method for detecting biomarkers |
| US20020137086A1 (en) * | 2001-03-01 | 2002-09-26 | Alexander Olek | Method for the development of gene panels for diagnostic and therapeutic purposes based on the expression and methylation status of the genes |
| US6949342B2 (en) * | 2001-12-21 | 2005-09-27 | Whitehead Institute For Biomedical Research | Prostate cancer diagnosis and outcome prediction by expression analysis |
| CA2469089A1 (en) * | 2003-07-08 | 2005-01-08 | Institut De Recherches Cliniques De Montreal | En-2 gene, disgnostic and therapeutic uses thereof |
| US20060014301A1 (en) | 2004-07-13 | 2006-01-19 | Power3 Medical Products, Inc. | Antibody-based system for detection of differential protein expression patterns |
| ES2534139T3 (es) * | 2004-12-02 | 2015-04-17 | Epigenomics Ag | Métodos y ácidos nucleicos para el análisis de la expresión génica asociada con el pronóstico de trastornos proliferativos de células de próstata |
| WO2006089091A2 (en) * | 2005-02-18 | 2006-08-24 | Memorial Sloan-Kettering Cancer Center | Methods for detecting minimum residual disease |
-
2006
- 2006-12-19 GB GBGB0625321.5A patent/GB0625321D0/en not_active Ceased
-
2007
- 2007-10-10 GB GBGB0719792.4A patent/GB0719792D0/en not_active Ceased
- 2007-12-19 CA CA2671939A patent/CA2671939C/en active Active
- 2007-12-19 PL PL07848631T patent/PL2115472T3/pl unknown
- 2007-12-19 RU RU2009127774/15A patent/RU2460075C2/ru not_active IP Right Cessation
- 2007-12-19 JP JP2009542216A patent/JP5683108B2/ja not_active Expired - Fee Related
- 2007-12-19 DK DK07848631.3T patent/DK2115472T3/da active
- 2007-12-19 PT PT78486313T patent/PT2115472E/pt unknown
- 2007-12-19 SI SI200731399T patent/SI2115472T1/sl unknown
- 2007-12-19 MX MX2009006378A patent/MX2009006378A/es active IP Right Grant
- 2007-12-19 CN CN200780051417.9A patent/CN101675341B/zh not_active Expired - Fee Related
- 2007-12-19 ES ES07848631.3T patent/ES2445185T3/es active Active
- 2007-12-19 US US12/518,708 patent/US8460882B2/en active Active
- 2007-12-19 NZ NZ577548A patent/NZ577548A/en not_active IP Right Cessation
- 2007-12-19 EP EP07848631.3A patent/EP2115472B1/en not_active Not-in-force
- 2007-12-19 WO PCT/GB2007/004902 patent/WO2008075056A1/en not_active Ceased
- 2007-12-19 AU AU2007335999A patent/AU2007335999B2/en not_active Ceased
- 2007-12-19 BR BRPI0720371A patent/BRPI0720371B8/pt not_active IP Right Cessation
-
2009
- 2009-06-08 IL IL199241A patent/IL199241A/en active IP Right Grant
-
2014
- 2014-02-05 CY CY20141100091T patent/CY1115178T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2115472A1 (en) | 2009-11-11 |
| CA2671939A1 (en) | 2008-06-26 |
| BRPI0720371B1 (pt) | 2019-05-28 |
| CN101675341A (zh) | 2010-03-17 |
| PL2115472T3 (pl) | 2014-05-30 |
| AU2007335999A1 (en) | 2008-06-26 |
| GB0625321D0 (en) | 2007-01-24 |
| RU2009127774A (ru) | 2011-01-27 |
| SI2115472T1 (sl) | 2014-05-30 |
| AU2007335999B2 (en) | 2013-09-05 |
| MX2009006378A (es) | 2009-08-24 |
| CN101675341B (zh) | 2017-08-08 |
| RU2460075C2 (ru) | 2012-08-27 |
| GB0719792D0 (en) | 2007-11-21 |
| CA2671939C (en) | 2017-10-03 |
| PT2115472E (pt) | 2014-02-14 |
| IL199241A (en) | 2014-03-31 |
| DK2115472T3 (da) | 2014-02-10 |
| WO2008075056A1 (en) | 2008-06-26 |
| CY1115178T1 (el) | 2016-12-14 |
| US8460882B2 (en) | 2013-06-11 |
| NZ577548A (en) | 2012-03-30 |
| ES2445185T3 (es) | 2014-02-28 |
| EP2115472B1 (en) | 2013-11-06 |
| JP2010513901A (ja) | 2010-04-30 |
| BRPI0720371A2 (pt) | 2013-12-31 |
| US20100093558A1 (en) | 2010-04-15 |
| BRPI0720371B8 (pt) | 2021-07-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5683108B2 (ja) | 癌バイオマーカー | |
| JP4936887B2 (ja) | 胃ガンの検出用マーカー | |
| EP1996940B1 (en) | Detection of cancer by elevated levels of bcl-2 | |
| RU2596394C2 (ru) | Маркеры для рака эндометрия | |
| CN114250299A (zh) | 用于膀胱癌检测的尿标记物 | |
| WO2002064015A2 (en) | Pin1 as a marker for prostate cancer | |
| US20140248637A1 (en) | Composition for diagnosis of lung cancer and diagnosis kit of lung cancer | |
| US7951544B1 (en) | Method for determining the prognosis of cancer patients by measuring levels of bag expression | |
| EP3067698A1 (en) | Pd-ecgf as biomarker of cancer | |
| TWI539161B (zh) | 用於偵測胃癌之標識物 | |
| EP4363852A1 (en) | Method of detecting proteins in human samples and uses of such methods | |
| CN121023017A (zh) | 用于胰腺癌诊断和预后评估的arhgap42标志物及其应用 | |
| KR100980004B1 (ko) | 위암 진단 마커로서의 엠이엘케이 | |
| WO2010060032A1 (en) | Method for determining progression of ductal carcinoma in situ to invasive breast cancer | |
| AU2012216703A1 (en) | Markers for detection of gastric cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20101206 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101206 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20130308 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130514 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130814 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20140606 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20141006 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20141015 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20150106 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20150113 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 5683108 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |